| Eric W Taylor, MD | |
|
3841 Piper St, Suite T345, Anchorage, AK 99508-4624 | |
| (907) 565-6000 | |
| (907) 565-6000 |
| Full Name | Eric W Taylor |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 26 Years |
| Location | 3841 Piper St, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891752457 | NPI | - | NPPES |
| MD3335 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 4905 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner-university Medical Center South Campus | Tucson, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arizona Total Care Llc | 6800128539 | 22 |
| Banner -- University Medical Group | 7719899871 | 819 |
News Archive
Researchers at the Perelman School of Medicine at the University of Pennsylvania have put sleeplessness on the map - literally. The research team, analyzing nationwide data collected by the Centers for Disease Control and Prevention (CDC), has produced the first state-by-state sleep maps for the United States, revealing that residents of Southern states suffer from the most sleep disturbances and daytime fatigue, while residents on the West Coast report the least amount of problems.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.
A patient's own molecular data can be used to identify, with the use of artificial intelligence methods, the best combinatorial multi-drug therapy for that patient. Network modelling plays a major role in this line of work.
Finding relief from sciatica is imperative, and Gulf Coast Spine Care offers proven, effective treatment options for these individuals. Recently, the medical center has started offering additional treatment options for the benefit of its patients who suffer from this condition, and these treatments have provided patients with considerable improvement to their quality of life.
Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.
› Verified 6 days ago
| Entity Name | Banner -- University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508809427 PECOS PAC ID: 7719899871 Enrollment ID: O20031105000694 |
News Archive
Researchers at the Perelman School of Medicine at the University of Pennsylvania have put sleeplessness on the map - literally. The research team, analyzing nationwide data collected by the Centers for Disease Control and Prevention (CDC), has produced the first state-by-state sleep maps for the United States, revealing that residents of Southern states suffer from the most sleep disturbances and daytime fatigue, while residents on the West Coast report the least amount of problems.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.
A patient's own molecular data can be used to identify, with the use of artificial intelligence methods, the best combinatorial multi-drug therapy for that patient. Network modelling plays a major role in this line of work.
Finding relief from sciatica is imperative, and Gulf Coast Spine Care offers proven, effective treatment options for these individuals. Recently, the medical center has started offering additional treatment options for the benefit of its patients who suffer from this condition, and these treatments have provided patients with considerable improvement to their quality of life.
Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.
› Verified 6 days ago
| Entity Name | Arizona Total Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700433885 PECOS PAC ID: 6800128539 Enrollment ID: O20191030002591 |
News Archive
Researchers at the Perelman School of Medicine at the University of Pennsylvania have put sleeplessness on the map - literally. The research team, analyzing nationwide data collected by the Centers for Disease Control and Prevention (CDC), has produced the first state-by-state sleep maps for the United States, revealing that residents of Southern states suffer from the most sleep disturbances and daytime fatigue, while residents on the West Coast report the least amount of problems.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.
A patient's own molecular data can be used to identify, with the use of artificial intelligence methods, the best combinatorial multi-drug therapy for that patient. Network modelling plays a major role in this line of work.
Finding relief from sciatica is imperative, and Gulf Coast Spine Care offers proven, effective treatment options for these individuals. Recently, the medical center has started offering additional treatment options for the benefit of its patients who suffer from this condition, and these treatments have provided patients with considerable improvement to their quality of life.
Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.
› Verified 6 days ago
| Entity Name | Transitional Care Management Of Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891424784 PECOS PAC ID: 6901286509 Enrollment ID: O20220628003770 |
News Archive
Researchers at the Perelman School of Medicine at the University of Pennsylvania have put sleeplessness on the map - literally. The research team, analyzing nationwide data collected by the Centers for Disease Control and Prevention (CDC), has produced the first state-by-state sleep maps for the United States, revealing that residents of Southern states suffer from the most sleep disturbances and daytime fatigue, while residents on the West Coast report the least amount of problems.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.
A patient's own molecular data can be used to identify, with the use of artificial intelligence methods, the best combinatorial multi-drug therapy for that patient. Network modelling plays a major role in this line of work.
Finding relief from sciatica is imperative, and Gulf Coast Spine Care offers proven, effective treatment options for these individuals. Recently, the medical center has started offering additional treatment options for the benefit of its patients who suffer from this condition, and these treatments have provided patients with considerable improvement to their quality of life.
Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eric W Taylor, MD 3841 Piper St, Suite T345, Anchorage, AK 99508-4624 Ph: (907) 565-6000 | Eric W Taylor, MD 3841 Piper St, Suite T345, Anchorage, AK 99508-4624 Ph: (907) 565-6000 |
News Archive
Researchers at the Perelman School of Medicine at the University of Pennsylvania have put sleeplessness on the map - literally. The research team, analyzing nationwide data collected by the Centers for Disease Control and Prevention (CDC), has produced the first state-by-state sleep maps for the United States, revealing that residents of Southern states suffer from the most sleep disturbances and daytime fatigue, while residents on the West Coast report the least amount of problems.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.
A patient's own molecular data can be used to identify, with the use of artificial intelligence methods, the best combinatorial multi-drug therapy for that patient. Network modelling plays a major role in this line of work.
Finding relief from sciatica is imperative, and Gulf Coast Spine Care offers proven, effective treatment options for these individuals. Recently, the medical center has started offering additional treatment options for the benefit of its patients who suffer from this condition, and these treatments have provided patients with considerable improvement to their quality of life.
Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.
› Verified 6 days ago
Daniel Gregory Allen, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 673 Medical Group, Jb Elmendorf-richardson, Anchorage, AK 99506 Phone: 907-580-2181 | |
Robert D Wald, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2605 Denali St, Ste 203, Anchorage, AK 99503 Phone: 907-677-9253 Fax: 907-272-1553 | |
Dr. Sheila Joyce Clark, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 207 E Northern Lights Blvd, Ste 111, Anchorage, AK 99503 Phone: 907-272-1892 Fax: 907-272-0962 | |
Dr. David Michael Henzler, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1100 E Dimond Blvd, Anchorage, AK 99515 Phone: 907-565-6000 Fax: 907-565-6001 | |
Dr. Karen Jackman, M.D Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1675 C St, Suite 117, Anchorage, AK 99501 Phone: 907-274-8281 Fax: 907-274-4055 | |
Dr. Steven Edward Koehl, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 5955 Zeamer Ave, Anchorage, AK 99506 Phone: 907-580-2181 | |
Dr. Cathleen E Marshall, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3340 Providence Dr Ste A565, Anchorage, AK 99508 Phone: 907-212-2321 Fax: 907-212-8499 |